The device integrates advanced sensors, AI-driven decision-making and automated drug delivery with the goal of ensuring rapid epinephrine administration. The researchers are also focused on the device\u2019s manufacturability, security and integration for scalability.<\/p>\n\n\n\n
Hussain said the research aims to shrink the potentially dangerous gap between the start of an anaphylactic event and the administration of epinephrine to treat it.<\/p>\n\n\n\n
\u201cEpinephrine is effective in treating the event, but the patient or someone nearby must recognize that anaphylaxis is occurring, locate the injector, correctly decide to use it and physically administer it,\u201d he said. \u201cA person experiencing a severe reaction may be alone, confused, physically impaired, unconscious or simply unable to act quickly enough.\u201d<\/p>\n\n\n\n
Hussain disclosed the device to the Purdue Innovates Office of Technology Commercialization<\/a>, which has applied for a nonprovisional patent application to protect the intellectual property.<\/p>\n\n\n\n Industry partners interested in developing or commercializing the system should contact Parag Vasekar, business development and licensing manager-physical sciences, at psvasekar@prf.org<\/a> about track code 70551<\/a>.<\/p>\n\n\n\n Hussain said the envisioned wearable device monitors multiple physiological indicators associated with anaphylaxis.<\/p>\n\n\n\n \u201cBecause no single physiological signal necessarily provides sufficient information, multimodal sensing is important,\u201d he said.<\/p>\n\n\n\n Hussain said the AI component is intended to analyze the different signals, learn the wearer\u2019s physiological baseline, identify abnormal combinations consistent with an anaphylactic event, and distinguish a true emergency from normal physiological variations or false alarms.<\/p>\n\n\n\n \u201cOnce sufficient confidence is established, the system could alert the wearer and caregivers and ultimately initiate automated epinephrine delivery if appropriate safeguards are satisfied,\u201d he said.<\/p>\n\n\n\n Hussain said beyond anaphylaxis monitoring, the broader scientific idea behind the device interests him.<\/p>\n\n\n\n \u201cMost wearable healthcare devices today primarily sense and report,\u201d he said. \u201cWe are asking whether future wearables can sense, understand, decide and intervene. In that sense, this work is a step toward autonomous robotic systems for healthcare.\u201d<\/p>\n\n\n\n Hussain said the device is being validated through sensor optimization, AI-driven decision-making and automated drug delivery testing.<\/p>\n\n\n\n \u201cWe are testing microfluidic and spring-based injection systems, integrated power-efficient components and ensured data security using encrypted communication networks,\u201d he said. \u201cFunctionality, reliability and safety are being assessed through real-world simulations, industry collaboration and a figure-of-merit evaluation to optimize scalability and affordability.\u201d<\/p>\n\n\n\n Hussain and his team have been developing and prototyping elements of the mechanical injection system and associated electronics. He said the next major challenge is integration.<\/p>\n\n\n\n \u201cWe need to bring together the physiological sensors, signal-conditioning electronics, the edge-AI decision system \u2013 which processes data and makes decisions directly on the wearable device rather than relying on a remote computer or cloud \u2013 power management and the injection mechanism into progressively more integrated prototypes,\u201d he said.<\/p>\n\n\n\n Hussain said further development steps include validating reliability, documenting false-positive and false-negative rates, and understanding the appropriate regulatory and clinical validation pathways.<\/p>\n\n\n\n Hussain said the broader idea behind the device reflects a direction his research group has been pursuing for future wearable and intelligent electronic systems.<\/p>\n\n\n\n \u201cMost wearable healthcare devices today primarily sense, process and report information,\u201d he said. \u201cWe believe that is only part of what a truly intelligent wearable system should do. The next frontier is actuation. After sensing what is happening and intelligently determining what it means, the system should be capable of safely doing something about it.\u201d<\/p>\n\n\n\n Hussain\u2019s research has increasingly focused on the transition from passive monitoring toward closed-loop systems that integrate sensing, computation, decision-making and physical action. Applications could include drug delivery, electrical or mechanical stimulation, thermal intervention, microfluidic control or other physical responses.<\/p>\n\n\n\n \u201cWe are interested in completing the loop,\u201d Hussain said. \u201cA sensor gives a system awareness. Artificial intelligence can give it the ability to interpret and decide. But actuation gives it the ability to interact with the physical world. Bringing sensing, intelligence and actuation together can transform a wearable device from a monitor into an autonomous system.\u201d<\/p>\n\n\n\n The epinephrine project provides a particularly demanding example because the actuation is not merely informational. The system must make a highly consequential decision and physically deliver a therapeutic intervention. This requires reliability, fail-safe operation, low false-positive and false-negative rates, power efficiency, security and appropriate safeguards.<\/p>\n\n\n\n \u201cIn that sense, we are not simply developing another wearable sensor,\u201d Hussain said. \u201cWe are exploring the architecture of autonomous, closed-loop wearable systems that can sense, understand, decide and act. We believe this convergence of multimodal sensing, edge intelligence and actuation will be an important direction for the next generation of wearable and healthcare electronics.\u201d<\/p>\n\n\n\n The\u00a0Purdue Innovates Office of Technology Commercialization<\/a>\u00a0operates one of the most comprehensive technology transfer programs among leading research universities in the U.S. Services provided by this office support the economic development initiatives of Purdue University and benefit the university\u2019s academic activities through commercializing, licensing and protecting Purdue intellectual property. In fiscal year 2025, the office reported 161 deals executed with 269 technologies licensed, 479 invention disclosures received,\u00a0and 267 U.S. and international patents received. The office is managed by the Purdue Research Foundation, a private, nonprofit foundation created to advance the mission of Purdue University. Contact\u00a0otcip@prf.org<\/a>\u00a0for more information.\u00a0<\/p>\n\n\n\n Purdue University is a research institution ranked among the top 10 public universities in the United States. More than 111,000 students study at Purdue across multiple campuses, including more than 57,000 at our main campus locations in West Lafayette and Indianapolis. As a land-grant university committed to affordability and accessibility, Purdue\u2019s main campus has frozen tuition 14 years in a row, enabling more students than ever to graduate debt-free.<\/p>\n\n\nUsing AI to \u2018sense, understand, decide and intervene\u2019<\/h2>\n\n\n\n
![\"Three](\"https:\/\/www.purdue.edu\/newsroom\/wp-content\/uploads\/2026\/10\/Epipen-2.jpeg\" "\\"\\"")
Device validation and next development steps<\/h2>\n\n\n\n
Completing the loop to achieve actuation<\/h2>\n\n\n\n
About Purdue Innovates Office of Technology Commercialization<\/h2>\n\n\n\n
About Purdue University<\/h2>\n\n\n\n